• Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model 

      Camilio, Ketil Andre; Wang, Meng-Yu; Mauseth, Brynjar; Waagene, Stein; Kvalheim, Gunnar; Rekdal, Øystein; Sveinbjørnsson, Baldur; Mælandsmo, Gunhild M. (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-01-22)
      <i>Background</i> - Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death through the release of danger-associated molecular pattern molecules (DAMPs), LTX-315 is capable ...
    • Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model 

      Nestvold, Janne M.; Wang, Mengyu; Camilio, Ketil Andre; Zinöcker, Severin; Tjelle, Torunn Elisabeth; Lindberg, Alf; Haug, Bengt Erik; Kvalheim, Gunnar; Sveinbjørnsson, Baldur; Rekdal, Øystein (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-08-17)
      LTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model. The treatment was T-cell dependent, and also resulted in an abscopal effect as demonstrated by the regression of distal non-treated lesions. Significant infiltration ...